As of March 5, we've updated our corporate brand. We are in the process of updating our media library - in the meantime, please find new materials below.
updated Jan 2019
*This non-GAAP amount excludes significant upfront and milestone payments for business development transactions and other specified R&D items.?
OPDIVO?, $6.7 billion
ELIQUIS?, $6.4 billion
ORENCIA?, $2.7 billion
SPRYCEL?, $2.0 billion
YERVOY?, $1.3 billion
SUSTIVA? franchise, $283 million
REYATAZ? franchise, $427 million
Hepatitis C franchise, $17 million
Please click on the product links to see the Full Prescribing Information for BARACLUDE?, DAKLINZA?,ELIQUIS?, EMPLICITI?, OPDIVO?, ORENCIA?, REYATAZ?, SPRYCEL?, SUSTIVA?, and YERVOY?, including Boxed WARNINGS for BARACLUDE?, ELIQUIS?, and Boxed WARNINGS for YERVOY? regarding immune-mediated adverse reaction.
Bristol Myers Squibb Corporate B-roll
This B-roll includes a collection of footage of Bristol Myers Squibb campus exteriors, corporate signage, research and development, and manufacturing facilities.